Regulation Timeline

May 2021

MDR date of applicability. All Class 1 and Class III Custom devices must be compliant. Vigilance and PMS/PMCF Plans due for all devices. No significant changes can be made to existing MDD devices.

May 2022

Periodic safety update reports due for MDD and MDR compliant devices that require annual updates. IVDR date of applicability. EUDAMED live (device registration required 18 months after). IVD PMS/PMPF Plans due.

May 2023

PSURs for Class IIa will be due for MDR. PSURs due for Class C and D IVD products.

May 2024

All devices - including Class Ir - must be MDR and IVDR compliant. 

Will you be ready?

Helpful Resources

EU MDR Audits: Preparing, Managing and Responding [Webinar]
EU MDR 2017/745 Health Checklist [Blog]
Strategies for Successful IVDR Implementation [Webinar]

Why R&Q?

Expert implementers experienced with multinational companies transitioning to the EU MDR and IVDR

Validated EU MDR / IVDR transition process, procedures, and tools

Best-in-class project management and SMEs for all workstreams

Implementation of PMS / PMCF processes and plans

Former notified body senior leadership on staff

We do it all... or only what you need


Impact assessment

High-level examination of all items with significant impact. Up-classifications, lack of clinical evidence, own-brand labeling, QMS impact, economic operators, UDI, new testing requirements, and more…  


Foundation for alignment

Built based on the results of your impact assessment and includes a project charter and client-specific training program. It also includes a preliminary program plan, schedule, and budget.



Conduct gap assessment of every regulatory file (tech files and dossiers) or until consistent themes are identified to enable remediation planning. Then, gap to all elements of the MDR/IVDR. There is much more to this step! Contact us.



Plans developed include a regulatory impact plan which aligns your portfolio to MDD and MDR certification timelines (and more), quality plan for managing QMS changes, and an overall program management plan and schedule.



This includes effective program management and regulatory intelligence monitoring. Other critical aspects include establishing a program governance process to efficiently resolve questions and issues in a timely fashion. KPI’s are monitored and reported up effectively on all workstreams.  

Frequently asked questions

  • The transition period doesn’t end until May 2020. Why start now?

    2020 is not far away. Given the extensive amount of work that must happen between now and then, if you don’t start now, you won’t finish. The resources of the notified body and lead times will not be available. The closer to the 2020 date, the longer we’d expect the lead times to be...if you can even get the support. At the minimum, you must execute your plan and understand how big of a gap you have to fill between now and then. At least then you’ll know if your products are in good shape with only minor tweaks to make. Hitting that date will be impossible if the plan isn’t started today.

  • Can you provide any guidance on what is needed for State of the Art?

    The state of the art should include a summary of the clinical background for the corresponding medical field, a description of the medical alternatives available to the patient population, a summary of the applicable standards and guidance documents, and a conclusion regarding the subject device compared to the state of the art. The clinical background summary will include details on the medical condition, users, and patient populations. The description of the medical alternatives should include data on the safety and performance of benchmark/similar devices and alternative therapies as well as a summary of the advantages/disadvantages and benefits/risks of those alternatives. The state of the art should be supported by literature references identified through a systematic literature search. The amount of detail included in a state of the art is usually proportional to the complexity and risk of the device.

  • What is a 1R device?

    These are reusable devices.  This is a new classification and requires NB involvement, much like class I devices with a measuring function. The NB oversight is focused on activities such as sterilization between uses.

  • Can you give examples of minimal changes that would not trigger a need to move to MDR?

    This is a tough question as it will vary based on the risk class of the device and should really be discussed with your Notified body.  Some manufactures use a decision tree similar to the FDA decision tree for submitting 510(k)s to determine if a change is significant or not.   This doesn’t encompass everything that should be considered, but may be a good place to start.

  • What type of testing would be expected for disposal of devices?

    Safe disposal testing will vary based on the type of device.  Testing may include tests like validation of the cleaning or decontamination instructions for the device, verification of disposal method (i.e. can the device be incinerated?), or verification of safe disassembly instructions if device must be taken apart for disposal. 

  • What is / Is there a best way to map the EU-MDR regulation changes onto the stages in the manufacturing Life Cycle of Medical devices?

    We would say that there is not one best way. The MDR does have specific sections, but none identified as just applicable to manufacturing. For manufacturing, I would consider starting with requirements from Article 10 Section 9 (QMS), Annex I (GSPR) and Annex IX (Conformity Assessment).  Article 10 (9) and Annex IX will cover the most of the QMS requirements like Management reviews, CAPAs, Non-conformances, verification, complaints, etc., which may impact your manufacturing processes. Annex I will cover requirements like Risk and Manufacturing plans and validations which will be required and may impact the manufacturing lifecycle.

  • Are there any new requirements from a risk management documentation perspective?

    Yes, there is a requirement for a risk management plan that we have heard is more product specific than how it was utilized in the past.Additionally, it is expected that risk management is tied more closely with PMS activities. As such, if you have not done quantitative risk analysis in the past, it will be needed now.  =You will also have to update with real data on a more frequent basis depending on the classification of your device and how often you are creating PSURs or PMS Reports.

Contact us

Complete the form below and we'll respond within 48 hours.

Note: If you are interested in applying for a position at R&Q, please visit the careers page.